[Edaily Reporter Park Sun-Yeop ] Hanwha Ocean is trading higher in early trading following news that it has been selected as the preferred bidder for the detailed design and construction of the lead ship of the Korean Next-Generation Destroyer (KDDX) program. According to MP Doctor on the 2nd, as of 9:22 a.m. today, Hanwha Ocean(042660)is trading at 107,400 won, up 4,100 won (3.87%) from the previous trading day. In early trading, the stock surged as high as 115,900 won, a 12.20% increase. The stock’s strength is attributed to a regulatory filing released before the market opened today. Hanwha Ocean announced today that it had been selected as the preferred bidder for the detailed design and lead ship construction project for the KDDX destroyer, commissioned by the Defense Acquisition Program Administration (DAPA). The KDDX project is a large-scale defense project to develop and build the Navy’s next-generation destroyers using domestic technology. Hanwha Ocean’s selection as the preferred bidder appears to have boosted the stock price, reflecting expectations for enhanced competitiveness in future naval vessel projects and expanded order intake in the defense sector. However, this selection does not immediately imply the signing of a formal contract. Hanwha Ocean stated that the contract amount and duration are scheduled to be finalized following consultations between the parties. The final contract will be signed after negotiations on specific terms and conditions, and the company plans to issue another announcement with relevant details once they are confirmed. The company explained, “These details are subject to change as the project progresses.”
The biggest bottleneck for AI servers is memory. As the KV cache—where large language models (LLMs) store past computations—accumulates, the required memory capacity increases exponentially. This prob…
Concerns about “tax risks” have been raised in some quarters of the financial investment, pharmaceutical, and biotech markets regarding Genosco, a subsidiary of OSCOTEC Inc.(039200)specializing in new…
As July began (June 29–July 3), the pharmaceutical and biotech industries turned their attention to Celltrion Pharm Inc.’s large-scale investment in production facilities and AriBio’s successful fundr…